Key Takeaways
- Vanderbilt Health will lead the NIH‑funded Machine Learning/Artificial Intelligence Tools to Advance Genomic Translational Research (MAGen) consortium, serving as both coordinating center and a development site.
- The effort is backed by two five‑year NIH phased innovation awards projected to total $12.8 million, with funding for years 3‑5 contingent on meeting early‑stage milestones.
- Bradley Malin, PhD, will direct the coordinating center GenePath, which will unite experts in variant interpretation, protein function, genomics, anthropology, informatics, health equity, and ELSI to build generalizable AI tools.
- Lisa Bastarache, MS, will head one of MAGen’s three development sites at Vanderbilt, focusing on patient‑centered prediction of clinically important outcomes from pathogenic variants.
- Other development sites are led by Konrad Karczewski (Harvard/MGH) on ethically guided multimodal AI for disease pathogenesis, and Kuan‑Lin Huang (Icahn/Mount Sinai) on genomics‑empowered AI for personalized cancer risk.
- The consortium aims to move genomic associations from discovery to actionable clinical insights by leveraging machine learning and AI to predict how genetic variants cause disease in individuals.
Vanderbilt Secures Major NIH Funding to Lead Genomic‑AI Consortium
Vanderbilt Health has been awarded two complementary NIH phased innovation grants that together are expected to provide $12.8 million over five years to support the Machine Learning/Artificial Intelligence Tools to Advance Genomic Translational Research (MAGen) consortium. The initiative, launched by the National Institutes of Health, seeks to bridge the gap between genomic discovery and clinical application by harnessing machine learning and artificial intelligence (AI). Bradley Malin, PhD, the Accenture Professor and Professor of Biomedical Informatics, Biostatistics and Computer Science, will establish and lead the consortium’s coordinating center at Vanderbilt.
Coordinating Center GenePath Receives Initial $1.2 Million Award
Under the first NIH grant, Malin’s coordinating center—named GenePath (Genetic variant Evidence using Novel tools to Elucidate Pathophysiology: Accelerating Translation to Health)—receives a two‑year award of $1.2 million. Funding for years 3‑5 is projected to add another $3.6 million, contingent on achieving predefined milestones in the initial phase. Malin emphasized the transformative potential of the effort, stating:
“While decades of research have brought to light myriad associations of genetic variation with all manner of disease, many promised advances in genomic medicine and personalized treatment await a deepened understanding of how pathogenic variants become manifest in individuals. Machine learning and artificial intelligence carry tremendous promise for powering this critical field of inquiry, bringing new precision to bear on these questions, and ultimately rendering more genomic information actionable in the clinic.”
GenePath will serve as the intellectual hub of MAGen, convening Vanderbilt experts across variant interpretation, protein function, genomic medicine, genetic anthropology, informatics, health equity, consortium coordination, and ethical, legal, and social implications (ELSI). Its structure includes a scientific operations unit, a data and machine learning unit tasked with creating a common data model and cross‑validation protocols, and an engagement in ELSI unit designed to ensure ongoing dialogue with patients, families, communities, and providers.
Leadership Team Brings Interdisciplinary Expertise
Malin serves as the contact principal investigator and project leader for GenePath. He is joined by co‑principal investigators Jada Benn Torres, PhD, Associate Professor of Anthropology, and Wei‑Qi Wei, MD, PhD, Professor of Biomedical Informatics. This multidisciplinary team reflects the consortium’s goal of integrating biological insight with computational rigor and societal awareness.
Lisa Bastarache Heads Vanderbilt Development Site with $3.2 Million Initial Grant
In parallel, Lisa Bastarache, MS, Research Associate Professor of Biomedical Informatics, has secured a phased innovation award of $3.2 million for years 1‑2 to establish one of MAGen’s three development sites at Vanderbilt Health. Anticipated funding for years 3‑5 totals an additional $4.8 million, again tied to milestone achievement. Bastarache’s site will focus on “Patient‑centered prediction of clinically important outcomes arising from pathogenic variants.”
The other two development sites are located at:
- Massachusetts General Hospital (Harvard University), led by Konrad Karczewski, PhD, pursuing ethically guided multimodal AI models for predicting disease pathogenesis in individuals with pathogenic variants; and
- Icahn School of Medicine at Mount Sinai, led by Kuan‑Lin Huang, PhD, working on genomics‑empowered AI for personalized cancer risk assessment, monitoring, and prevention.
Consortium-Wide Vision: From Variant to Action
MAGen’s overarching ambition is to translate the wealth of genotype‑phenotype associations uncovered over the past decade into predictive, explainable tools that clinicians can use at the point of care. By applying machine learning algorithms to large, integrated genomic and phenotypic datasets, the consortium hopes to elucidate how specific genetic changes lead to disease manifestations in individual patients—a question that has long limited the utility of genomic data in routine medicine.
As Malin noted, the effort will produce “generalizable and accessible tools to predict and explain how variants cause disease in individuals,” thereby moving genomic information from a research curiosity to a tangible asset for personalized treatment planning.
Grant Numbers and Administrative Details
The coordinating center GenePath is supported by NIH grant 1UG3HG014374, while Bastarache’s development site operates under NIH grant 1UG3HG014376. Both awards follow the NIH phased innovation model, which releases later‑year funding only after early‑stage objectives are met, ensuring that resources are directed toward projects demonstrating tangible progress.
Implications for Vanderbilt and Genomic Medicine
Vanderbilt’s dual role as coordinating center and development site positions it at the forefront of a national effort to operationalize AI‑driven genomics. The infusion of nearly $13 million will not only expand faculty and staff capacity but also foster cross‑institutional collaboration that could accelerate the deployment of AI‑based decision support tools in hospitals and clinics nationwide.
In sum, the MAGen consortium represents a concerted push to convert decades of genetic discovery into concrete clinical benefits. Through the leadership of Bradley Malin and Lisa Bastarache, Vanderbilt is poised to help shape the next generation of genomic medicine—where machine learning transforms raw variant data into actionable insights for patients and providers alike.
$12.8m grant to lead initiative to get genomics toward the clinic via machine learning and AI